Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

Nov 30 2010

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial. A new patent application has been filed for novel dosing combinations of RVX-208 and leading statin therapeutics. The patent was filed based on the results demonstrated in the ASSERT trial. Resverlogix' findings in a post-hoc analysis of ASSERT data revealed that RVX-208 in certain doses along with leading statin drugs markedly improved not only ApoA-I production, HDL and large HDL particles, but also important aspects of LDL and ApoB particles.  All of these positive changes took place in patients on the best standard of care currently available.

"The bonus finding of ApoB and LDL lowering while on statins and not in placebo's was a surprise finding and is useful in selecting the best statin co-medications going forward for maximum treatment effect. The effects seem most efficacious in the leading stains, being Pfizer's Lipitor and AstraZeneca's Crestor. Resverlogix will further delineate this positive synergistic effect from a mechanistic point of view," stated Dr. Jan Johansson, Senior Vice President of Medical Affairs of Resverlogix. "To have these additional findings of unexpected enhanced statin performance, in combination with RVX-208, offers us an added approach to providing an array of new therapies to reduce atherosclerosis and coronary vascular disease," Dr. Johansson added.

"ASSERT, as it was designed to do, taught us several key findings," stated Kenneth Lebioda, Senior Vice President Business & Corporate Development of Resverlogix. "We now understand with greater clarity that RVX-208 works better in high risk patients with low HDL and that certain doses have far greater effect in promoting markers of reverse cholesterol transport (RCT). After careful analysis of all the data we also found that when RVX-208 is used with certain statins we see significant reductions in liver signals such as ALTs while still maintaining very good efficacy. These key findings have helped us immensely in designing a more powerful, accurate and targeted ASSURE Phase 2b trial.  In terms of business development this new patent filing greatly expands the scope of our commercial program," Lebioda added.